- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03679741
Initial Evaluation of Investigational Lenses Manufactured on a New Production Line
December 12, 2019 updated by: Johnson & Johnson Vision Care, Inc.
This study is a randomized, 4-visit, subject-masked, 2x3 bilateral crossover, dispensing trial.
Each study lens will be worn bilaterally in a daily wear (DW) modality for at least 6 hours per day and 5 days per week for approximately two weeks each.
The subject will wear either the Test or Control lens twice and the other study lens once.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
126
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Randall Go, OD
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- VRC-East
-
-
New York
-
Vestal, New York, United States, 13850
- Sacco Eye Group
-
-
South Carolina
-
Pickens, South Carolina, United States, 29671
- Pickens Eye Care
-
-
Utah
-
Salt Lake City, Utah, United States, 29671
- William J. Bogus, OD, FAAO
-
-
Virginia
-
Roanoke, Virginia, United States, 24153
- Botetourt Eyecare, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject must read and sign the Informed Consent form.
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Healthy adult males or females age ≥18 and ≤49 years of age with signed informed consent. Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them.
- The subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and -6.00 D.
- The subject's refractive cylinder must be ≤ 1.00 D in each eye.
- The subject must have visual acuity best correctable to 20/25+3 or better for each eye.
- Subjects must own a wearable pair of spectacles.
- The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of DW per day, at least 5 days per week, for a minimum of 1 month prior to the study) and willing to wear the study lenses on a similar basis.
- Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week.
- The subject must have normal eyes (i.e., no ocular medications or infections of any type).
Exclusion Criteria:
- Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
- Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
- Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral (e.g., Chlor-Trimeton, and Benadryl) and ophthalmic antihistamines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), oral and ophthalmic Beta-adrenergic blockers (e.g., Propranolol, Timolol, and Practolol), systemic steroids, and any prescribed or over the counter (OTC) ocular medication.
- Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion.
- Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), LASIK, etc.).
- Any Grade 3 or greater slit lamp findings (e.g.., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
- Any known hypersensitivity or allergic reaction to Optifree® PureMoist® multi-purpose care solution or Eye-Cept® rewetting drop solution.
- Any ocular infection, allergy or clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study.
- Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
- Toric, extended wear, monovision or multi-focal contact lens correction.
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
- Participation in clinical trials involving the Test lens within 3 months prior to study enrollment.
- History of binocular vision abnormality or strabismus.
- Employee, relative or friends of employees of any ophthalmic company, or investigational clinic (e.g., Investigator, Coordinator, Technician).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: TEST/CONTROL/CONTROL
Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences.
Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
|
Acuvue OASYS
senofilcon A
|
|
EXPERIMENTAL: CONTROL/TEST/TEST
Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences.
Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
|
Acuvue OASYS
senofilcon A
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Comfort Score
Time Frame: 2-Week Follow-up
|
Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
|
2-Week Follow-up
|
|
Vision Satisfaction in Bright Lighting
Time Frame: 2-Week Follow-up
|
Vision satisfaction in bright light was assessed using the individual item" I was satisfied with the quality of my vision in bright lighting" from the CLUE™ questionnaire.
This item used the response scale, 1: Strongly Disagree, 2: Disagree, 3: Neither Agree nor Disagree, 4: Agree and 5: Strongly Agree.
CLUE is the Contact Lens User Experience™ questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
The Proportion of responses in each category were reported for each lens type.
|
2-Week Follow-up
|
|
Distance Monocular LogMAR Visual Acuity
Time Frame: 2-Week Follow-up
|
Distance Monocular LogMAR visual acuity was assessed at 4 meters using an ETDRS chart under high illumination low contrast (room illumination > 400 lux and chart luminance 120-200 cd/m2) and low illumination high contrast (room illumination <2.5 lux and chart luminance 2.0 - 5.0 cd/m2 at the 2-week follow-up for each subject eye.
The average visual acuity for each lens was reported.
|
2-Week Follow-up
|
|
Contact Lens Fitting Acceptance Rate
Time Frame: Up to 2-Week Follow-up
|
Contact lens fitting acceptance was assessed for each subject eye using a biomicroscope at all study visits.
Lens fit was a binary variable where acceptable lens fit=1 and unacceptable lens fit=0.
The percentage of eyes with acceptable lens fit was reported for each lens.
|
Up to 2-Week Follow-up
|
|
Number of Grade 3 or Higher Slit Lamp Findings
Time Frame: Up to 2-Week Follow-up
|
Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e.
Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
This was performed on each subject eye at every study visit (baseline, unscheduled visits and 2-week follow-up).
The data was then dichotomized into two groups.
Those with grade 3 or higher and those with grade 2 or lower.
The proportion of eyes with SLF with grade 3 or higher by lens was reported.
|
Up to 2-Week Follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Quality of Vision Score
Time Frame: 2-Week Follow-up
|
Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
|
2-Week Follow-up
|
|
Overall Handling Scores
Time Frame: 2-Week Follow-up
|
Overall handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire.
CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65.
Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
|
2-Week Follow-up
|
|
Overall Quality of Vision Indoors
Time Frame: 2-Week Follow-up
|
Overall Quality of Vision Indoors was assessed using the individual item" Overall Quality of Vision Indoors" from questionnaire assessing contact lens performance.
This item used the response scale, 0: Not Applicable, 1: Excellent, 2: Very Good, 3: Good, 4: Fair and 5: Poor.
The Proportion of responses in each category were reported for each lens type.
|
2-Week Follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 29, 2018
Primary Completion (ACTUAL)
October 31, 2018
Study Completion (ACTUAL)
October 31, 2018
Study Registration Dates
First Submitted
September 19, 2018
First Submitted That Met QC Criteria
September 19, 2018
First Posted (ACTUAL)
September 20, 2018
Study Record Updates
Last Update Posted (ACTUAL)
December 26, 2019
Last Update Submitted That Met QC Criteria
December 12, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- CR-6283
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visual Acuity
-
Mayo ClinicNot yet recruitingVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Alcon ResearchQueensland University of TechnologyCompleted
-
Alcon ResearchCompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
Clinical Trials on CONTROL Lens
-
CooperVision, Inc.CompletedMyopiaUnited States
-
CooperVision, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedOcular PhysiologyUnited States
-
CooperVision, Inc.Completed
-
CooperVision, Inc.Centre for Ocular Research & Education, CanadaCompleted
-
CooperVision, Inc.CORECompleted
-
Johnson & Johnson Vision Care, Inc.CompletedOcular PhysiologyUnited States
-
CooperVision, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Bruno Vision Careiuvo BioScience Operations, LLCCompleted